55 results about "Chickenpox" patented technology

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

Disclosed are an mRNA vaccine encoding a varicella zoster virus (VZV) protein, a preparation method therefor, and use thereof. The mRNA vaccine is characterized by encoding at least the varicella zoster virus (VZV) gE protein, gH protein, and gL protein.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

Described are modified Varicella Zoster Virus glycoprotein E (VZV gE) proteins having improved stability and / or immunogenicity compared to a non-modified VZV gE. Also described are associated nucleic acids, immunogenic compositions, and methods of using such modified VZV gE proteins in the treatment or prevention of shingles.

The present disclosure provides methods of inducing an immune response against varicella zoster virus (VZV) in a human subject. The methods provided herein comprise administering to a human subject an immunogenic composition (e.g., a vaccine) comprising an RNA molecule formulated in a lipid nanoparticle. The disclosure also relates to the use of the immunogenic composition for the prevention or treatment of herpes zoster in a human subject.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

A pharmaceutical composition comprising: i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them; ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide. Use of the pharmaceutical composition in the preparation of a medicament for preventing and / or treating a varicella-zoster virus infection and / or a varicella-zoster virus mediated disease. The pharmaceutical composition achieves an unexpected technical effect and can mediate a stronger immune response.

The invention discloses an immunogenic composition containing gE nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biomedicine, the immunogenic composition comprises self-assembled gE nanoparticles and an oil-in-water emulsion adjuvant, and a self-assembled gE nanoparticle antigen comprises gE, a connecting peptide SGS and a gI polypeptide sequence containing Th epitopes; the oil-in-water type emulsion adjuvant is prepared from squalene, Tween 80, DL-alpha-tocopherol and / or Span 85. The immunogenic composition provided by the invention can be applied to vaccines for preventing varicella and / or herpes zoster and / or postherpetic neuralgia, so that the aims of improving the immunogenicity of the gE antigen and reducing side effects of the vaccines are fulfilled.

The invention discloses a gE fusion protein containing a gH Th epitope and a preparation method and application thereof, and relates to the technical field of biomedicine, the fusion protein comprises a varicella-zoster virus (VZV) glycoprotein E extracellular domain (gE) and a Th epitope-containing VZV glycoprotein H extracellular domain (gH) polypeptide. The gE fusion protein can be applied to VZV vaccines, and solves the technical problems of weak immunogenicity of gE antigens and serious side reaction of vaccines in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the gE fusion protein as the antigen has the advantages that the variety and dosage of immunopotentiators are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the gE fusion protein vaccine not only can induce a gE specific CMI reaction, but also can induce a gH specific CMI reaction, so that the effectiveness of the vaccine is further improved. In short, the gE fusion protein has good clinical application potential.

Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antiviral compounds, especially against adenoviruses, coronaviruses, and varicella zoster viruses, are also provided.

The present disclosure belongs to the technical field of mRNA vaccines, and specifically relates to a herpes zoster mRNA vaccine, a preparation method therefor, and a use thereof. The herpes zoster mRNA vaccine provided by the present disclosure comprises an RNA encoding a varicella-zoster virus gE glycoprotein or a variant thereof. The vaccine can prevent herpes zoster infection and its complications.

Embodiments of the present disclosure generally relate to a new class of compositions that include VZV IE62 or a derivative thereof (e.g., a mutant) and lipid particles. Embodiments of the present disclosure also relate to uses of the compositions for treating, alleviating, or reducing the severity of, various diseases or medical conditions in a patient. For example, embodiments described herein may be utilized for treating, alleviating, or reducing the severity of various neuroinflammation and related pathologies and diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, neuromyelitis optica, or dementia, among others.

To provide herpes zoster mRNA vaccine, a preparation method therefor, and use thereof.SOLUTION: Provided is a herpes zoster mRNA vaccine, comprising an RNA encoding a varicella-zoster virus gE glycoprotein or a variant thereof, wherein the vaccine can prevent herpes zoster infection and its complications.SELECTED DRAWING: Figure 2

The present application relates to the field of immunological detection, and particularly relates to a reagent for detecting varicella-zoster virus infection and a preparation method thereof. The reagent comprises R1 reagent and R2 reagent; the R1 reagent is a working solution of streptavidin magnetic beads, and the preparation method comprises the following steps: firstly coupling activated carboxyl magnetic beads with streptavidin; dialyzing the magnetic beads obtained by the first coupling to remove streptavidin physically combined with the magnetic beads; secondly coupling the dialyzed magnetic beads with streptavidin; quenching the magnetic beads obtained by the second coupling, and then placing the magnetic beads in a working solution to obtain the working solution; the working solution contains fetal bovine serum, bovine serum albumin and lysine; the R2 reagent is a biotinylated VZV gE recombinant protein, and the VZV gE recombinant protein is a varicella-zoster virus gE glycoprotein extracellular domain fragment expressed by human embryonic kidney cells. The reagent has high sensitivity and specificity in the detection of varicella-zoster virus infection.

The invention discloses a gene for coding soluble VZV-gB-SpyTag protein and application of the gene, and belongs to the technical field of genetic engineering and immunology. The nucleotide sequence of the gene is as shown in SEQ ID NO. 8. The invention provides a gene for coding soluble VZV-gB-SpyTag as well as a recombinant plasmid and a recombinant microorganism thereof, soluble VZV-gB-SpyTag protein is prepared, Fe-gB nanoparticles are further constructed, the nanoparticles are uniform in size, good in dispersity and stable in structure, the cellular immune effect of the VZV-gB protein can be remarkably improved, and the VZV-gB-SpyTag protein can be used for preparing the soluble VZV-gB-SpyTag protein. The resistance of the body to varicella-zoster virus is enhanced. The invention provides technical support for prevention and treatment of varicella-zoster virus.

The present application relates to the technical field of biological medicine, in particular to a preparation method of varicella attenuated live vaccine, a freeze-drying protective agent and application thereof, which comprises the steps of cell culture, virus infection, complex enzymatic dissociation, protective ultrasonic disruption, clarification and collection, etc. The complex enzymatic dissociation adopts EDTA and recombinant trypsin combination to loosen the cells at low temperature; the protective ultrasonic disruption adopts a buffer solution containing trehalose and recombinant human blood albumin to resuspend the cells and perform intermittent ultrasonic disruption. The present application further provides a freeze-drying protective agent which is composed of trehalose, sorbitol, L-arginine, L-histidine and polyvinylpyrrolidone. The virus harvesting efficiency of the method is high, and the virus activity loss is small; the freeze-drying protective agent has good safety and excellent stability.

The application discloses a plant-expressed varicella-zoster virus gB recombinant antigen and a preparation method, product and application thereof, and belongs to the technical field of plant molecular biology and vaccine engineering. The technical problems to be solved are that the existing VZV gB protein has low heterologous expression, poor stability and insufficient antigen activity; the existing VZV vaccine has high production cost, is difficult to popularize and has a single antigen with an immune escape risk; and the plant expression system is not mature in VZV gB antigen production, and lacks a complete preparation scheme and related products. The technical solution is that the natural VZV gB protein is modified, a furin protease cleavage site is knocked out, and a H527P mutation is introduced, related nucleic acid molecules, vectors and plant source cells are constructed, high-activity antigens are obtained through culture and purification, and the high-activity antigens are applied to the preparation of VZV drugs / vaccines, and have the advantages of low cost, high safety and strong immunogenicity.

Provided herein are varicella-zoster virus vaccine, human papilloma virus vaccine, and rabies vaccine antigens, compositions thereof, and uses thereof in cancer immunotherapy and treatment of cancer.

This invention relates to the field of biomedical technology, specifically to a stabilized and modified herpes zoster virus gE protein, its preparation method, and its applications. The stabilized and modified herpes zoster virus gE protein of this invention is obtained through cysteine ​​mutation modification and structural design optimization, and exhibits improved expression levels, thermal stability, and immunogenicity compared to recombinant varicella-zoster virus gE protein with only the removal of the carboxyl-terminal hydrophobic transmembrane region and intracellular tail.

The application belongs to the technical field of biological detection, and particularly relates to an isothermal amplification detection reagent and kit for detecting varicella-zoster virus (VZV). The application designs a specific primer pair with a target of a conservative region of an ORF62 of a VZV genome, performs RPA reaction, combines a modified detection probe, and uses lateral flow chromatography test paper to realize a detection sensitivity of not higher than 1 copy / µL for a crude extract of a vesicle fluid or throat swab sample, realize rapid and high-sensitivity detection, and has good popularization and application value.

In an embodiment, the invention is directed to prodrug compounds of L-BHDU according to the chemical structure I:Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok— R2a group;R1a is independently a C6-C30alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group;R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group;Each j is independently 1-6, 1-3, often 1 or 2;Each k is 0 or 1;Each n is independently 1-6, 1-4, 2-4 or 2 or 3; orA pharmaceutically acceptable salt, solute or polymorph thereof. Additional embodiments are directed to pharmaceutical compositions based upon the disclosed chemical compounds and methods of treating or reducing the likelihood of VZV, HSV-1 or HSV-2 infections. Methods of synthesizing compounds according to the present invention represent further embodiments of the invention.

The invention discloses self-assembled gE nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biomedicine. The self-assembled gE nanoparticle is formed by polymerizing a plurality of monomers, and the monomers comprise a varicella-zoster virus gE and a varicella-zoster virus gI polypeptide containing a Th epitope. The self-assembled gE nanoparticles provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the self-assembled gE nano-particle as the antigen has the advantages that the variety and dosage of an immunopotentiator are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the self-assembled gE nanoparticle vaccine not only can induce a gE specific CMI reaction, but also can induce a gI specific CMI reaction, so that the effectiveness of the vaccine is further improved. In a word, the self-assembled gE nanoparticles have good clinical application potential.

The present disclosure relates to circular RNA sequences encoding an antigen from varicella zoster virus (VZV). The circular RNA sequences described herein are used as vaccines and compositions for preventing or treating diseases resulting from VZV, including shingles. Methods of use, including methods of treating or preventing a disease caused by VZV and methods for formulating and preparing the VZV vaccine compositions, are also described.

The application discloses a kind of detection varicella-zoster virus LAMP-CRISPR reaction tube, kit and method, belong to biological detection technical field.The application provides a kind of detection varicella-zoster virus LAMP-CRISPR reaction tube, the reaction tube includes the LAMP reaction system freeze-dried microspheres placed in the bottom of pipe, and the CRISPR detection system freeze-dried powder sprayed on the pipe cover;The LAMP reaction system includes the LAMP primer group of nucleic acid sequence such as SEQ ID NO:2~7;The CRISPR detection system includes the crRNA of nucleic acid sequence such as SEQ ID NO:8.The LAMP-CRISPR reaction tube of the application uses "one-step method" single-tube closed-tube operation, only needs to be added to LAMP-CRISPR reaction tube after sample processing can carry out detection, and detection result is specific, and sensitivity is high.

The present application relates to the technical field of biological medicine, in particular to a kind of stable modified varicella-zoster virus gE protein, its preparation method and application.The stable modified varicella-zoster virus gE protein of the present application is obtained by cysteine mutation modification and structure design optimization, compared with the recombinant varicella-zoster virus gE protein with only carboxy-terminal hydrophobic transmembrane region and intracellular tail removed, has improved expression, thermal stability and immunogenicity.

The present disclosure provides a vaccine against herpes zoster, the herpes zoster vaccine comprising or encoding a varicella zoster virus (VZV) antigen, capable of eliciting an effective neutralizing antibody response against varicella zoster virus (VZV).

The present application relates to the technical field of biotechnology, in particular to a kind of multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcus and varicella-zoster virus infection and its preparation method and application.The immunogenic composition of the present application comprises:at least one pneumococcal polysaccharide-protein conjugate, wherein the pneumococcal polysaccharide is connected with carrier protein by covalent bond;The carrier protein is varicella-zoster virus glycoprotein E, i.e.VZV gE recombinant protein, and its amino acid sequence is shown as SEQ ID NO:3 or SEQ ID NO:4.The immunogenic composition containing multivalent pneumococcal polysaccharide-protein conjugate provided by the present application shows significant synergistic effect, realizes "double enhancement" effect.